Braga Estêvão Luiz Carvalho, Verçosa Nubia, Cavalcanti Ismar Lima
Department of General and Specialized Surgery, Medical Sciences Postgraduate Program, Fluminense Federal University, Niterói, Brazil.
Department of Surgery/Anaesthesiology, Surgical Sciences Postgraduate Program, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Front Pharmacol. 2022 May 11;13:915347. doi: 10.3389/fphar.2022.915347. eCollection 2022.
To test the hypothesis that the single use of fosaprepitant is not inferior to the use of palonosetron as antiemetic prophylaxis in the first 48 h after surgery in women undergoing laparoscopic cholecystectomy. Eighty-eight nonsmoking women (American Society of Anesthesiologists physical status I or II) aged between 18 and 60 years who underwent laparoscopic cholecystectomy received 150 mg of fosaprepitant or 75 μg of palonosetron, administered intravenously after the induction of general anesthesia. In the fosaprepitant group and in the palonosetron group, 13.6 and 18.2% of the patients, respectively, vomited in the first 48 h after surgery ( = 0.560). There were no differences between groups in the total frequency and intensity of nausea, number of complete responders, need for rescue medication, time required for the first rescue medication dose or number of adverse events. The administration of a single dose of fosaprepitant after the induction of anesthesia was as effective as the administration of a single dose of palonosetron for the prophylaxis of vomiting in the first 48 h after surgery in women undergoing laparoscopic cholecystectomy.
对于接受腹腔镜胆囊切除术的女性患者，单剂量使用福沙匹坦在术后48小时内作为预防性止吐药并不劣于帕洛诺司琼。88名年龄在18至60岁之间、接受腹腔镜胆囊切除术的非吸烟女性（美国麻醉医师协会身体状况I或II级）在全身麻醉诱导后静脉注射150毫克福沙匹坦或75微克帕洛诺司琼。在福沙匹坦组和帕洛诺司琼组中，分别有13.6%和18.2%的患者在术后48小时内呕吐（P = 0.560）。两组在恶心的总频率和强度、完全缓解者数量、急救药物需求、首次使用急救药物剂量所需时间或不良事件数量方面均无差异。麻醉诱导后单剂量使用福沙匹坦与单剂量使用帕洛诺司琼在预防接受腹腔镜胆囊切除术的女性患者术后48小时内呕吐方面效果相当。
